On the use of corticosteroids for 2019-nCoV pneumonia
In their Comment about the use of corticosteroids to treat 2019 novel coronavirus (2019-nCoV) lung injury, Clark Russell and colleagues 1 summarise the available clinical evidence on corticosteroid to treat patients with severe human coronavirus infections (severe acute respiratory syndrome [SARS] coronavirus and Middle East respiratory syndrome coronavirus), and other severe respiratory virus infections. In accordance with current WHO guidance, 2 Russell and colleagues 1 recommend that corticosteroids should not be used in 2019-nCoV-induced lung injury or shock, except in the setting of a clinical trial. The Comment 1 contributes to a better understanding of corticoste roid treatment in viral pneumonia. However, as a team of front-line physicians from China, we have a different perspective.
As mentioned by the authors, 1 the studies referred to in the paper were mostly observational studies. In clinical settings, physicians tend to use corticosteroids in the most critically ill patients. Therefore, selection bias and confounders in observational studies might contribute to any observed increased mortality in patient groups treated with corticosteroids. Although attempts were made to adjust for confounding factors in the studies, conclusive inference should not be made. Also, we question the interpretation of the systematic review about effective treatments for SARS. 3 Russell and colleagues state that "four studies provided conclusive data, all indicating harm". 1 These four studies were not definitive and only showed evidence of possible harm, whereas the results of 25 other studies were inconclusive, leading the original authors to state that the totality of data are inconclusive, and because of methodological limi-tations, it was not possible to make any recommendation. Inconclusive clinical evidence should not be a reason for abandoning corticosteroid use in 2019-nCoV pneumonia.
Moreover, there are studies supporting the use of corticosteroids at low-to-moderate dose in patients with coronavirus infection. For example, in a retrospective study of 401 patients with SARS, 4 proper use of corticosteroids was found to reduce mortality and shorten the length of stay in hospital for critically ill patients with SARS without causing secondary infection and other complications. Relevant research has also been done for other virus-associated respiratory diseases, such as influenzaassociated pneumonia. For example, in a prospective cohort study enrolling 2141 patients with influenza A (H1N1)pdm09 viral pneumonia from 407 hospitals in China, 5 low-tomoderate dose of corticosteroids (25-150 mg/day methylprednisolone or equivalent) reduced mortality in patients with oxygen index lower than 300 mm Hg. Besides, a systematic review 6 suggested corticosteroids could reduce mortality and the need for mechanical ventilation in patients with severe community-acquired pneumonia.
Because of methodological limitations in the available evidence, the use of corticosteroids remains controversial. We acknowledge the potential risks associated with highdose corticosteroids in treating 2019-nCoV pneumonia, such as secondary infec tions, long-term complications, and prolonged virus shedding. However, in critically ill patients, the overwhelming inflammation and cytokine-related lung injury might cause rapidly progressive pneumonia. Given the inconclusive evidence and urgent clinical demand, physicians from the Chinese Thoracic Society have developed an expert consensus statement on the use of corticosteroids in 2019-nCoV pneumonia. 7 All members of the expert panel participated in treating patients with 2019-nCoV pneumonia. The expert consensus statement is based both on the available published scientific literature and relevant research by panel members, and it was brought together through e-mail correspondence and online meetings.
According to the expert consensus statement, the following basic principles should be followed when using corticosteroids: (1) the benefits and harms should be carefully weighed before using cortico steroids; (2) corticosteroids should be used prudently in critically ill patients with 2019-nCoV pneumonia; (3) for patients with hypoxaemia due to underlying diseases or who regularly use corticosteroids for chronic diseases, further use of corticosteroids should be cautious; and (4) the dosage should be lowto-moderate (≤0·5-1 mg/kg per day methylprednisolone or equiva lent) and the duration should be short (≤7 days).
Corticosteroid treatment is a doubleedged sword. In line with the expert consen sus, we oppose liberal use of corticosteroids and recommend short courses of corticosteroids at low-tomoderate dose, used prudently, for critically ill patients with 2019-nCoV pneumonia. Existing evidence is inconclusive, and even systematic reviews and meta analyses on this topic reach differing conclusions. Therefore, in line with Russell and colleagues, 1 we believe that there is a need for well designed randomised controlled trials in the future to promote a more solid foundation for treatment recommendations.
We declare no competing interests. JZ, YH, RD, and BC are members of the panel that created the expert consensus statement on the use of corticosteroids in patients with 2019-nCoV pneumonia. We thank Zhenshun Cheng, Yang Jin, Min Zhou, Jing Zhang, and Jieming Qu for contributing to the development of the expert consensus on the use of corticosteroids in patients with 2019-nCoV pneumonia. We extend great thanks to Peter W Horby and Frederick G Hayden for assistance in writing this Correspondence. Broad dissemination in both Chinese and English will accomplish the goals of communicating timely and crucial findings to the international scientific community, while also disseminating this information to health-care workers on the frontline who need to understand the epidemiological and clinical features of COVID-19. This strategy will improve effective control strategies to ultimately contain the virus and protect the health of the public. in Nature, 2 at least 54 academic papers about COVID-19 were published in English-language journals by Jan 30, 2020. We searched major Chinese databases including the China National Knowledge Internet and WANFANG Data. As of Feb 3, 2020, just 23 Chineselanguage papers on COVID-19 were published. These publications mainly focused on epidemiology, clinical features of COVID-19, and the structure or genetics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Many of the research papers about COVID-19 in international journals were written by researchers in China, which led to great concerns because these findings cannot directly benefit frontline health professionals and policy makers because of the language barrier. It is critical for health science to be published in English-language journals to facilitate communication and enable global coordination and timely epidemic response. However, some media were concerned that Chinese researchers within academic organisations concentrated on publishing papers in prestigious international journals but paid inadequate attention to epidemic prevention of COVID-19 and neglected to disseminate their findings within Chinese-language journals. 3, 4 A recent statement by the Ministry of Science and Technology of China also encouraged researchers to focus their efforts on epidemic prevention and to publish their results in Chinese. 5 The emphasis on publishing clinical research in English helps to facilitate knowledge exchange between Chinese scientists and the rest of the world. We hope the research community will make efforts to disseminate all findings relevant to the outbreak of COVID-19 in Chinese in addition to English publishing outlets.
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